PHARMACY

Mylan gets FDA green light for generic Canasa
Mylan has received the FDA's OK for generic Canasa, which had a market value of roughly $263 million.
Glenmark gets FDA's blessing for two generics
The FDA has approved Glenmark's generics DermOtic Oil and Westcort ointment, which had a market value of about $18.1 million, and $11.1 million respectively.

Novadoz gets FDA green light for generic Rapaflo

Novadoz has received FDA clearance for generic Rapaflo, which is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.
Walgreens, Verily partner on health innovation

Walgreens Boots Alliance will be working with Verily, an Alphabet company, on multiple projects under an agreement focused on outcomes for patients with chronic conditions and lowering the cost of care.
AstraZeneca, Merck's Lynparza is approved by FDA

Lynparza is the first PARP inhibitor approved for first-line maintenance in BRCAm advanced ovarian cancer.
Rite Aid, McKesson ink 10-year distribution deal

Through a new 10-year agreement, McKesson will provide Ride Aid with brand and generic drugs through March 2029.
Ananda Professional studies CBD’s effect on tapering opioid usage

Ananda Professional announced its sponsorship of a study that showcases how hemp-derived CBD can affect a patient’s willingness to taper their opioid usage in a positive way.
Sandoz, Gan & Lee ink deal to develop insulin biosimilars

Sandoz and Gan & Lee plan to bring biosimilar versions of glargine, lispro and aspart to market.
Hikma launches generic Ampyra

Hikma is introducing its generic Ampyra, which had a market value of about $543 million in 2017.
Mylan launches generic Lialda

The Food and Drug Administration has approved Mylan's generic Lialda, which had a market value of roughly $842 million for the year ended Oct. 31, according to IQVIA data.